Is Enjamb Labs profitable?

No revenue figures are publicly disclosed. Enjamb Labs is a pre-seed startup that has raised $650,000 total from Y Combinator and Founders, with only 2 employees as of mid 2026, according to CB Insights and YC listings.

Could Veeva replace Enjamb Labs?

Veeva Systems announced its Falcon agentic platform on 2026-05-27, targeting the same regulatory and clinical drafting workflows Enjamb sells, with Regulatory agents due August 2026 and Clinical agents due December 2026, per Veeva's own investor release.

Who are Enjamb Labs' main competitors?

Enjamb Labs competes with Veeva Systems (Falcon platform, announced 2026-05-27) and Certara, which serves 2,600+ biopharma clients and partnered with NVIDIA on the BioNeMo Agent Toolkit on 2026-07-07, per company press releases.

Who owns Enjamb Labs?

Enjamb Labs is privately held, founded in 2025 and based in San Francisco. It has raised $650,000 total from Y Combinator and an entity listed as Founders, per CB Insights; no acquisition or parent company has been reported.

What speed does Enjamb Labs claim for FDA submissions?

Enjamb Labs claims (vendor-claimed, unverified) it can produce an FDA submission package in 48 hours versus a traditional 8 months, and claims 23x fewer errors than GPT-5.5, per its own website enjamb.org.

What is Enjamb Labs' biggest competitive threat?

Veeva Systems, the dominant life-sciences system-of-record vendor, shipped its own Falcon agentic platform the same week Enjamb publicly launched (2026-05-27 vs 2026-05-28), directly targeting Enjamb's regulatory and clinical drafting workflow.

YC Spring 2026 · United States

Enjamb Labs

Software that runs drug development programs from discovery to FDA filing.

Little protection left

Assessed 27 July 2026 · Evidence as of 27 July 2026

Not much stands between this business and its pressures.

On the recordSince 27 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Veeva Falcon Regulatory agents scheduled to launch

The call

Enjamb is a two-person, two-month-old company trying to automate drug submissions right as Veeva, the incumbent record-keeper, builds the same agents in-house.

Enjamb Labs builds software to automate the tedious back-and-forth tasks pharma companies do when submitting new drugs for approval, coordinating regulatory paperwork, clinical data, and statistical analysis. The problem is that Veeva Systems, which already owns the core database where pharma companies store their submission records and has relationships with over 2,600 drug makers, announced in May 2026 that it is shipping the exact same AI orchestration feature into its own system by August 2026. Enjamb claims it can work without moving data, but Veeva has no reason to let a standalone tool sit between itself and its customers, and frontier AI models like Claude can do orchestration without proprietary lock-in. The one thing that could change the picture is if Veeva's product launch slips more than three months past August, or if Enjamb's five named customers publicly confirm they are actually using the software and saving money with it, neither of which has happened yet.

Why

AI pressure: Frontier LLMs (Claude, GPT) sold directly into pharma workflows. Enjamb is built on top of Claude/GPT with no proprietary data; the model labs could sell the same orchestration straight to pharma. Could AI do the core job? Yes, likely.

Bigger players: Veeva Systems (Falcon platform, Regulatory agents due Aug 2026, Clinical agents due Dec 2026). Veeva already holds the pharma system of record and 2,600+ biopharma relationships, and is adding the same regulatory and clinical agents. Could a giant copy it? Yes, easily.

What protects it. Nothing verified yet: no proprietary data, no confirmed customer, and no regulatory foothold that Veeva or a model lab can't reach.

What would change this call

Veeva Falcon Regulatory agents ship on schedule around August 2026. Shows incumbent can deliver the same capability natively, closing Enjamb's window.
Veeva Falcon Clinical agents ship around December 2026 with pharma adoption. Would confirm incumbent distribution beats independent orchestration layers.
One of J&J, AbbVie, BMS, Merck, or Sanofi independently confirms Enjamb usage or ROI in press. Would validate Enjamb's customer claims beyond its own marketing.

Key numbers

Raised $650K total from YC and Founders (2026)
Team of 2 co-founders, 0 job postings (2026)
Veeva Falcon regulatory agents due Aug 2026 (2026-07)

Named risks

Veeva and Certara are shipping native agentic features into the exact same submission and clinical workflows Enjamb targets. Severity: high
Two person team and only $650,000 raised leave thin runway against well-capitalized incumbents. Severity: high
No proprietary data, FDA qualification, or system-of-record ownership to defend the workflow layer. Severity: high
Pharma customer usage claims (J&J, AbbVie, BMS, Merck, Sanofi) are vendor-authored and unverified by any named company. Severity: medium
Repositioning from broad R&D lifecycle tool to narrow drug-program tool suggests unstable pitch. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Veeva Systems	losing to	Falcon agentic platform announced 2026-05-27, Regulatory agents due Aug 2026, same workflow as Enjamb
Certara	losing to	Partnered with NVIDIA BioNeMo Agent Toolkit 2026-07-07, serves 2,600+ biopharma clients already
Benchling, Medidata, SAS	contesting	Enjamb claims to layer on top of these systems without data migration (vendor-claimed positioning)

Questions people ask

Is Enjamb Labs profitable?: No revenue figures are publicly disclosed. Enjamb Labs is a pre-seed startup that has raised $650,000 total from Y Combinator and Founders, with only 2 employees as of mid 2026, according to CB Insights and YC listings.
Could Veeva replace Enjamb Labs?: Veeva Systems announced its Falcon agentic platform on 2026-05-27, targeting the same regulatory and clinical drafting workflows Enjamb sells, with Regulatory agents due August 2026 and Clinical agents due December 2026, per Veeva's own investor release.
Who are Enjamb Labs' main competitors?: Enjamb Labs competes with Veeva Systems (Falcon platform, announced 2026-05-27) and Certara, which serves 2,600+ biopharma clients and partnered with NVIDIA on the BioNeMo Agent Toolkit on 2026-07-07, per company press releases.
Who owns Enjamb Labs?: Enjamb Labs is privately held, founded in 2025 and based in San Francisco. It has raised $650,000 total from Y Combinator and an entity listed as Founders, per CB Insights; no acquisition or parent company has been reported.
What speed does Enjamb Labs claim for FDA submissions?: Enjamb Labs claims (vendor-claimed, unverified) it can produce an FDA submission package in 48 hours versus a traditional 8 months, and claims 23x fewer errors than GPT-5.5, per its own website enjamb.org.
What is Enjamb Labs' biggest competitive threat?: Veeva Systems, the dominant life-sciences system-of-record vendor, shipped its own Falcon agentic platform the same week Enjamb publicly launched (2026-05-27 vs 2026-05-28), directly targeting Enjamb's regulatory and clinical drafting workflow.

Timeline

2026-12Veeva Falcon Clinical agents due to ship (planned)
2026-08Veeva Falcon Regulatory agents due to ship (planned)
2026-07-07Certara partners with NVIDIA on BioNeMo Agent Toolkit, serving 2,600+ biopharma clients
2026-06-16YC P26 batch report notes 137 of 196 companies build LLM agents
2026-05-28Enjamb Labs publicly launches on Y Combinator's Launch platform
2026-05-27Veeva Systems announces Falcon agentic platform for drug development
2026-04-07Veeva announces AI Agents rollout across all applications, Dec 2025 to Dec 2026
2025-10-21Certara joins Veeva AI Partner Program for regulatory submissions
2025Enjamb Labs founded in San Francisco

Revision history

27 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Kinect RentAHuman Aster